Addressing ethical challenges in HIV prevention research with people who inject drugs

被引:11
|
作者
Dawson, Liza [1 ]
Strathdee, Steffanie A. [2 ]
London, Alex John [3 ]
Lancaster, Kathryn E. [4 ]
Klitzman, Robert [5 ]
Hoffman, Irving [4 ]
Rose, Scott [6 ]
Sugarman, Jeremy [7 ]
机构
[1] NIAID, Div Aids, NIH, 5601 Fishers Lane,Room 9G48, Bethesda, MD 20892 USA
[2] Univ San Diego, San Diego, CA 92110 USA
[3] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA
[4] Univ N Carolina, Chapel Hill, NC USA
[5] Columbia Univ, New York, NY USA
[6] Family Hlth Int, Durham, NC USA
[7] Johns Hopkins Univ, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
Research Ethics; Research on Special Populations; HIV Infection and AIDS; PLACEBO-CONTROLLED TRIALS; PERINATAL TRANSMISSION; INTERNATIONAL RESEARCH; RESEARCH PARTICIPANTS; DEVELOPING-COUNTRIES; LAW-ENFORCEMENT; USERS; CARE; POLICY; INFECTION;
D O I
10.1136/medethics-2015-102895
中图分类号
B82 [伦理学(道德学)];
学科分类号
摘要
Despite recent advances in HIV prevention and treatment, high HIV incidence persists among people who inject drugs (PWID). Difficult legal and political environments and lack of services for PWID likely contribute to high HIV incidence. Some advocates question whether any HIV prevention research is ethically justified in settings where healthcare system fails to provide basic services to PWID and where implementation of research findings is fraught with political barriers. Ethical challenges in research with PWID include concern about whether research evidence will be translated into practice; concerns that research might exacerbate background risks; and ethical challenges regarding the standard of HIV prevention in research. While these questions arise in other research settings, for research with PWID, these questions are especially controversial. This paper analyses four ethical questions in determining whether research could be ethically acceptable: (1) Can researchers ensure that research does not add to the burden of social harms and poor health experienced by PWID? (2) Should research be conducted in settings where it is uncertain whether research findings will be translated into practice? (3) When best practices in prevention and care are not locally available, what standard of care and prevention is ethically appropriate? (4) Does the conduct of research in settings with oppressive policies constitute complicity? We outline specific criteria to address these four ethical challenges. We also urge researchers to join the call to action for policy change to provide proven safe and effective HIV prevention and harm reduction interventions for PWID around the world.
引用
收藏
页码:149 / 158
页数:10
相关论文
共 50 条
  • [21] HIV TESTING AMONG PEOPLE WHO INJECT DRUGS IN IVANOVO AND NOVOSIBIRSK, RUSSIA
    King, Elizabeth J.
    Niccolai, Linda M.
    Eritsyan, Ksenia U.
    Heimer, Robert
    Levina, Olga S.
    CENTRAL EUROPEAN JOURNAL OF PUBLIC HEALTH, 2019, 27 (01) : 50 - 53
  • [22] Addressing the HIV/AIDS Epidemic Among Puerto Rican People Who Inject Drugs: The Need for a Multiregion Approach
    Deren, Sherry
    Gelpi-Acosta, Camila
    Albizu-Garcia, Carmen E.
    Gonzalez, Angel
    Des Jarlais, Don C.
    Santiago-Negron, Salvador
    AMERICAN JOURNAL OF PUBLIC HEALTH, 2014, 104 (11) : 2030 - 2036
  • [23] A collision of crises: Addressing an HIV outbreak among people who inject drugs in the midst of COVID-19
    Taylor, Jessica L.
    Ruiz-Mercado, Glorimar
    Sperring, Heather
    Bazzi, Angela R.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2021, 124
  • [24] Prevention of Viral Hepatitis and HIV Infection among People Who Inject Drugs: A Systematic Review and Meta-Analysis
    Chen, Yen-Ju
    Lin, Yu-Chen
    Wu, Meng-Tien
    Kuo, Jenn-Yuan
    Wang, Chun-Hsiang
    VIRUSES-BASEL, 2024, 16 (01):
  • [25] Racial Inequities in HIV Prevalence and Composition of Risk Networks Among People Who Inject Drugs in HIV Prevention Trial Network 037
    Momplaisir, Florence
    Hussein, Mustafa
    Tobin-Fiore, Danielle
    Smith, Laramie
    Bennett, David
    Latkin, Carl
    Metzger, David S.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 76 (04) : 394 - 401
  • [26] The prevalence of people who inject drugs among those with HIV late presentation: a meta-analysis
    Farhadian, Negin
    Matin, Behzad Karami
    Farnia, Vahid
    Zamanian, Mohammad Hossein
    Najafi, Farid
    Farhadian, Maryam
    SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY, 2022, 17 (01)
  • [27] Impact of opioid substitution therapy on the HIV prevention benefit of antiretroviral therapy for people who inject drugs
    Mukandavire, Christinah
    Low, Andrea
    Mburu, Gitau
    Trickey, Adam
    May, Margaret T.
    Davies, Charlotte F.
    French, Clare E.
    Looker, Katharine J.
    Rhodes, Tim
    Platt, Lucy
    Guise, Andy
    Hickman, Matthew
    Vickerman, Peter
    AIDS, 2017, 31 (08) : 1181 - 1190
  • [28] The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs?
    Harris, Magdalena
    Albers, Eliot
    Swan, Tracy
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2015, 26 (10) : 963 - 969
  • [29] Candidate hepatitis C vaccine trials and people who inject drugs: Challenges and opportunities
    Maher, Lisa
    White, Bethany
    Hellard, Margaret
    Madden, Annie
    Prins, Maria
    Kerr, Thomas
    Page, Kimberly
    VACCINE, 2010, 28 (45) : 7273 - 7278
  • [30] An assessment of an HIV prevention intervention among People Who Inject Drugs in the states of Manipur and Nagaland, India
    Goswami, Prabuddhagopal
    Medhi, Gajendra Kumar
    Armstrong, Gregory
    Setia, Maninder Singh
    Mathew, Shajan
    Thongamba, Gay
    Ramakrishnan, Lakshmi
    George, Bitra
    Singh, Rakesh Kumar
    Paranjape, Ramesh S.
    Mahanta, Jagadish
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2014, 25 (05) : 853 - 864